Immuneering Corp (NASDAQ: IMRX) kicked off on Monday, up 5.81% from the previous trading day, before settling in for the closing price of $1.63. Over the past 52 weeks, IMRX has traded in a range of $1.00-$8.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -43.59% over the past five years. While this was happening, its average annual earnings per share was recorded 3.19%. With a float of $22.40 million, this company’s outstanding shares have now reached $31.05 million.
Let’s look at the performance matrix of the company that is accounted for 68 employees. In terms of profitability, gross margin is 100.58%, operating margin of 65.47%, and the pretax margin is 15506.24%.
Immuneering Corp (IMRX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Immuneering Corp is 27.87%, while institutional ownership is 14.04%. The most recent insider transaction that took place on Apr 01 ’24, was worth 1,160,181. In this transaction 10% Owner of this company sold 400,000 shares at a rate of $2.90, taking the stock ownership to the 2,895,273 shares. Before that another transaction happened on Mar 22 ’24, when Company’s Director bought 2,900 for $2.55, making the entire transaction worth $7,385. This insider now owns 2,900 shares in total.
Immuneering Corp (IMRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 3.19% per share during the next fiscal year.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
Take a look at Immuneering Corp’s (IMRX) current performance indicators. Last quarter, stock had a quick ratio of 7.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.97, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
Immuneering Corp (NASDAQ: IMRX) saw its 5-day average volume 2.15 million, a positive change from its year-to-date volume of 2.14 million. As of the previous 9 days, the stock’s Stochastic %D was 14.09%. Additionally, its Average True Range was 0.20.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 25.80%, which indicates a significant increase from 25.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 103.08% in the past 14 days, which was lower than the 133.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0503, while its 200-day Moving Average is $1.9332. Nevertheless, the first resistance level for the watch stands at $1.8200 in the near term. At $1.9100, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.0200. If the price goes on to break the first support level at $1.6200, it is likely to go to the next support level at $1.5100. The third support level lies at $1.4200 if the price breaches the second support level.
Immuneering Corp (NASDAQ: IMRX) Key Stats
The company with the Market Capitalisation of 44.58 million has total of 31,050K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -53,470 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -14,600 K.
